Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson’s disease

被引:0
|
作者
Huimin Chen
Jinping Fang
Fangfei Li
Liyan Gao
Tao Feng
机构
[1] Capital Medical University,Department of Neurology, Center for Neurodegenerative Disease, Beijing Tiantan Hospital
[2] Beijing institute for brain disorders,Parkinson’s Disease Center
[3] China National Clinical Research Center for Neurological Diseases,undefined
来源
Neurological Sciences | 2015年 / 36卷
关键词
Parkinson’s disease; Wearing-off; Levodopa; Safe dosage;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of this study was to investigate the risk factors of wearing-off phenomenon in Parkinson’s disease (PD) and propose safe dosage of levodopa to reduce wearing-off development based on Chinese cohort. Patients with PD who had taken levodopa (l-dopa) for at least 1 month were recruited. Wearing-off was diagnosed based on validated Chinese version of a patient self-rated 9-question Wearing-Off Questionnaire (WOQ-9) and clinical definition. Eleven variables (gender, disease duration at l-dopa initiation, disease duration at assessment, age at onset, age at assessment, H-Y stage, UPDRS III, l-dopa daily total dosage and dosage adjusted to weight, duration of l-dopa treatment, initial drug recipe) were included in our analysis. Univariate analysis, multivariate logistic regression analysis and decision tree classification model(DTC) were used to detect risk factors of wearing-off. Receiver operating characteristic (ROC) curve and DTC were used to investigate cut-off value of l-dopa to best predict wearing-off. Two hundred and thirty-four patients were investigated in our study, among whom 111 developed wearing-off. Patients with wearing-off tended to receive higher l-dopa dosage and endure longer duration of l-dopa treatment. l-Dopa dosage as 281 mg/day and 4.2 mg/kg/day by ROC, as well as 269 mg/day and 3.2 mg/kg/day by DTC were cut-off values for wearing-off. l-Dopa dosage and duration of l-dopa treatment were related to increased wearing-off development. Cumulative l-dopa dosage and l-dopa daily dosage were better predictive of wearing-off. Inadequate evidence was present for delayed l-dopa initiation. l-Dopa daily dosage no more than 275 mg or 4.2 mg/kg was regarded as safe.
引用
收藏
页码:1217 / 1223
页数:6
相关论文
共 50 条
  • [31] Difference in perception of the wearing-off between patients and physicians in Parkinson's disease
    Tsuboi, Y.
    Nakagawa, R.
    Ishido, M.
    Yoshinaga, Y.
    Hashimoto, T.
    Mishima, T.
    Fujioka, S.
    [J]. MOVEMENT DISORDERS, 2019, 34 : S257 - S257
  • [32] The availability of LSVT-BIG for Parkinson's disease patients with wearing-off
    Tomiyama, Masahiko
    Nunomura, Jinichi
    Sasaki, Megumi
    Ueno, Tatsuya
    Haga, Rie
    Funamizu, Yukihisa
    Kon, Tomoya
    Nishijima, Haruo
    Arai, Akira
    Suzuki, Chieko
    [J]. MOVEMENT DISORDERS, 2014, 29 : S34 - S35
  • [33] Wearing-Off Scales in Parkinson's Disease: Critique and Recommendations
    Antonini, Angelo
    Martinez-Martin, Pablo
    Chaudhuri, Ray K.
    Merello, Marcelo
    Hauser, Robert
    Katzenschlager, Regina
    Odin, Per
    Stacy, Mark
    Stocchi, Fabrizio
    Poewe, Werner
    Rascol, Oliver
    Sampaio, Cristina
    Schrag, Anette
    Stebbins, Glenn T.
    Goetz, Christopher G.
    [J]. MOVEMENT DISORDERS, 2011, 26 (12) : 2169 - 2175
  • [34] Shortness of Breath, a 'Wearing-Off' Symptom in Parkinson's Disease
    Khan, Waqas
    Naz, Sughra
    Rana, Abdul Qayyum
    [J]. CLINICAL DRUG INVESTIGATION, 2009, 29 (10) : 689 - 691
  • [35] Shortness of Breath, a ‘Wearing-Off’ Symptom in Parkinson’s Disease
    Waqas Khan
    Sughra Naz
    Abdul Qayyum Rana
    [J]. Clinical Drug Investigation, 2009, 29 : 689 - 691
  • [36] Wearing-off of levodopa of greatest concern for PD patients
    Lieberman, A.
    Vijay, M.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 109 - 109
  • [37] Significant benefits of the direct switch from conventional levodopa/henserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with early wearing-off
    Eggert, K.
    Oertel, W. H.
    Skogar, Oe.
    Amar, K.
    Luotonen, L.
    Nissinen, H.
    [J]. MOVEMENT DISORDERS, 2008, 23 (01) : S215 - S215
  • [38] Significant benefits of the direct switch from conventional levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with early wearing-off
    Eggert, K.
    Oertel, W.
    Skogar, O.
    Amar, K.
    Luotonen, L.
    Nissinen, H.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 125 - 125
  • [39] Wearing-off in Parkinson's disease: neuropsychological differences between on and off periods
    Caillava-Santos, Fabiane
    Margis, Regina
    de Mello Rieder, Carlos Roberto
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 1175 - 1180
  • [40] Frequency and phenomenology of motor and non-motor features of wearing-off phenomenon in Brazilian Parkinson's disease patients
    Cardoso, F.
    Cesar, B. P.
    Teixeira, A. L., Jr.
    Camargos, S. T.
    Maia, D. P.
    Cunningham, M. C.
    [J]. MOVEMENT DISORDERS, 2007, 22 : S195 - S195